Added to YB: 2026-04-03
Pitch date: 2026-03-31
ANAB [neutral]
AnaptysBio, Inc.
+3.13%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Market Cap
$1.6B
Pitch Price
$55.93
Price Target
N/A
Dividend
N/A
EV/EBITDA
30.85
P/E
-120.38
EV/Sales
6.70
Sector
Biotechnology
Category
special_situation
Show full summary:
AnaptysBio (ANAB) spin-off
ANAB (update): Approved spin of First Tracks (TRAX), trading ~Apr 6. Separates royalty biz (Jemperli royalties from GSK + imsidolimab milestones/royalties from VNDA) from clinical-stage biotech. Different fundamentals/valuations may create trading opportunity.
Read full article (1 min)